Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
基本信息
- 批准号:9355470
- 负责人:
- 金额:$ 94.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-21 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAcuteAcute Lung InjuryAcute respiratory failureAddressAdult Respiratory Distress SyndromeAlveolarAlveolar Cell Type IApoptosisAreaCell Differentiation processCellsChronicClinicalCytokeratin 17DevelopmentDiffuseDistalEndothelial CellsEngraftmentEpithelialEpithelial CellsEquilibriumGasesGenesGoalsGraft SurvivalHistologyHomeostasisHumanHypoxiaImmunosuppressionIn VitroInfluenzaInjection of therapeutic agentInjuryLeadLungLung diseasesMacacaMethodologyModelingMolecularMonkeysMusNatural regenerationNecrosisOrganPathway interactionsPharmacologyPhasePrimatesProcessProtocols documentationPulmonary Surfactant-Associated Protein CPulmonologyReplacement TherapyReportingResearch PersonnelRespiratory physiologySignal TransductionStem cellsStressSupportive careSurfaceTestingTherapeuticToxic effectTranslationsTransplantationType II Epithelial Receptor CellUndifferentiatedcapillary bedcell motilityexperimental studyfunctional improvementimprovedin vivoinduced pluripotent stem cellinjury and repairlung hypoxialung injurylung repairmigrationmouse modelnotch proteinnovel therapeutic interventionprogenitorprogramsregenerativerepairedscreeningself-renewalstemtooltranslation to humans
项目摘要
ABSTRACT
The overall goal of this application is to develop a compelling rationale and workable methodology for the
treatment of diffuse alveolar damage with transplanted human epithelial stem/progenitor cells capable of long
term engraftment and improved organ function. Stem/progenitor replacement therapy is envisioned as a
meaningful therapeutic adjunct in several clinical situations dominated by diffuse alveolar damage with
epithelial loss: severe, acute lung injury, e.g. due to influenza or other causes of ARDS, as well as acute
exacerbations of chronic fibrotic lung disease. Recent studies discussed in the application indicate effective
alveolar regeneration, and thus improved lung function, requires both a first phase of expansion and migration
of stem/progenitor cells to re-establish alveolar barriers followed by a second phase of differentiation of new
barrier cells into mature type II (AEC2s) and type I alveolar cells. To develop a translational program for
alveolar regeneration by transplantation of healthy lung epithelial stem/progenitor cells, three basic objectives
are advanced: (1) Further delineation of the signaling programs by which endogenous human distal lung
epithelial stem cells can be activated following major injury to establish new alveolar barriers and then
differentiate to AEC2s. (2) In vitro development of pools of human distal (small airway and alveolar) epithelial
stem cells, both endogenous and iPSC-derived, suitable for transplantation and directed differentiation in mice.
Distal basal-like cells from human iPS cells using gene edited cells reporting surfactant protein C, cytokeratin
17 (Krt17), and NKX2.1 will be used to develop a workable protocol for directed differentiation after transplant.
(3) Employ models of lung repair/regeneration approachable by transplantation as tools to assess the
regenerative potential of human epithelial stem/progenitor cells. Macaque iPS cells suitable for
transplantation into influenza-infected monkeys will be used as a primate model for therapy. It is anticipated
that functional improvement in gas exchange and alveolar histology can be achieved in primates, providing
both a rationale and methodology for stem/progenitor cells as adjunctive therapy after severe acute lung injury
in humans.
摘要
这个应用程序的总体目标是开发一个令人信服的理由和可行的方法
人上皮干/祖细胞移植治疗弥漫性肺泡损伤
终末期植入和改善器官功能。干细胞/祖细胞替代疗法被设想为一种
在以弥漫性肺泡损伤为主的几种临床情况下有意义的治疗辅助药物
上皮丢失:严重的急性肺损伤,例如由于流感或其他原因引起的ARDS,以及急性
慢性纤维性肺病的恶化。最近在应用程序中讨论的研究表明有效
肺泡再生,从而改善肺功能,需要第一阶段的扩张和迁移。
干细胞/祖细胞重建肺泡屏障,随后进行新生细胞第二阶段分化
屏障细胞分化为成熟的II型(AEC2s)和I型肺泡细胞。要为以下项目开发翻译程序
健康肺上皮干/祖细胞移植的肺泡再生:三个基本目标
提出:(1)进一步描述内源性人类远端肺的信号程序
严重创伤后上皮干细胞可以被激活,以建立新的肺泡屏障,然后
区分为AEC2。(2)人远端(小气道和肺泡)上皮池的体外发育
干细胞,既有内源性的,也有IPSC来源的,适合移植并在小鼠体内定向分化。
使用报告表面活性蛋白C和细胞角蛋白的基因编辑细胞从人iPS细胞中分离出远端基底样细胞
17(Krt17),和Nkx2.1将用于开发移植后定向分化的可行方案。
(3)使用可通过移植获得的肺修复/再生模型作为评估
人上皮干/祖细胞的再生潜能。猕猴iPS细胞适用于
移植到感染流感的猴子身上将被用作治疗的灵长类动物模型。这是意料之中的
灵长类动物在气体交换和肺泡组织学方面的功能改善可以实现,为
干细胞/祖细胞作为严重急性肺损伤后辅助治疗的理论和方法学
在人类身上。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Harold A Chapman其他文献
Harold A Chapman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Harold A Chapman', 18)}}的其他基金
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
IPF 患者口服表没食子儿茶素-3-没食子酸酯 (EGCG) 的 1 期研究
- 批准号:
10702133 - 财政年份:2022
- 资助金额:
$ 94.83万 - 项目类别:
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
IPF 患者口服表没食子儿茶素-3-没食子酸酯 (EGCG) 的 1 期研究
- 批准号:
10418169 - 财政年份:2022
- 资助金额:
$ 94.83万 - 项目类别:
Program to promote lung regeneration and block fibrosis
促进肺再生和阻止纤维化的计划
- 批准号:
9893639 - 财政年份:2020
- 资助金额:
$ 94.83万 - 项目类别:
Program to promote lung regeneration and block fibrosis
促进肺再生和阻止纤维化的计划
- 批准号:
10570862 - 财政年份:2020
- 资助金额:
$ 94.83万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
10181019 - 财政年份:2016
- 资助金额:
$ 94.83万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
10418711 - 财政年份:2016
- 资助金额:
$ 94.83万 - 项目类别:
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
上皮干细胞/祖细胞修复受损肺
- 批准号:
9109038 - 财政年份:2015
- 资助金额:
$ 94.83万 - 项目类别:
Identification, Isolation, and Reprogramming Alveolar Epithelial Progenitor Cells
肺泡上皮祖细胞的鉴定、分离和重编程
- 批准号:
7676645 - 财政年份:2008
- 资助金额:
$ 94.83万 - 项目类别:
Urokinase Receptor Integrin Interactions in Lung Cancer
肺癌中尿激酶受体整合素相互作用
- 批准号:
7318124 - 财政年份:2007
- 资助金额:
$ 94.83万 - 项目类别:
Urokinase Receptor Integrin Interactions in Lung Cancer
肺癌中尿激酶受体整合素相互作用
- 批准号:
8079454 - 财政年份:2007
- 资助金额:
$ 94.83万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 94.83万 - 项目类别: